Cann Group Ltd. · ASX:CAN
Cann — Investor Presentation (April 2023)
16 slides from Cann's investor presentation, Apr 17, 2023
Slide 1: ASX Announcement: Investor presentation
ASX ANNOUNCEMENT 17 April 2023 Investor presentation For personal use only 17 April 2023 – As announced on 5 April 2023, Cann Group Limited (ASX: CAN) (Cann or the Company) will be presenting an investor update webinar and Q&A, hosted by CEO, Peter Koetsier. The webinar will be held today, Monday, 1
Slide 2: Moving to scaled production with a focus on quality, reliability and innovation
For personal use only Moving to scaled production with a focus on quality, reliability and innovation April 2023 Peter Koetsier Chief Executive Officer 1
Slide 3: Disclaimer | Important notice
Disclaimer | Important notice This presentation (Presentation) has been prepared by Cann Group Limited (ABN 25 603 949 739) (Cann). For personal use only Summary information This Presentation contains summary information about Cann and its activities which is current as at the date of this Presentat
Slide 4: Highlights
For personal use only Highlights • Positive early impressions reinforced • Mildura facility secures strong competitive advantage • Production is quickly moving to scale • Market opportunity is substantial and growing • Sales momentum is strong with positive outlook • Satipharm platform provides uniq
Slide 5: Positive early impressions reinforced
For personal use only Positive early impressions reinforced • Strong team of talented and experienced people at Cann • Medicinal cannabis market is growing rapidly • Cann has successfully established an integrated B2B business model of Australian grown product • Mildura facility is a world-class pro
Slide 6: Mildura facility secures strong competitive advantage
Mildura facility secures strong competitive advantage For personal use only • A microclimate-controlled glasshouse with manufacturing and warehouse space • Automated plant movement conveyors and plant propagation systems • In-house analytical chemistry and microbiology laboratories • Satipharm manuf
Slide 7: We are at a transition point in the business
For personal use only We are at a transition point in the business 2017 – 2022 2023 and beyond START UP AND BUILD SCALE AND SELL Agri & engineering innovation Commercial leadership • Establish core build of Mildura facility • Operationalise Mildura facility • Ensure agricultural standards met • Comm
Slide 8: Mildura production is quickly moving to scale
Mildura production is quickly moving to scale QUARTERLY WET BIOMASS OUTPUT For personal use only 10,000 Historical Planned* 9,000 8,000 7,000 Wet Biomass Yield, kg 6,000 5,000 4,000 3,000 2,000 1,000 0 Q2 CY22 Q3 CY22 Q4 CY22 Q1 CY23 Q2 CY23 Q3 CY23 Q4 CY23 Q1 CY24 Inhalation Extraction * Note: plan
Slide 9: Sales momentum is strong with a positive outlook
For personal use only Sales momentum is strong with a positive outlook $ Million 6 month Revenue A$ 10 9 8 7 6 5 4 3 2 1 0 Dec-20 Jun-21 Dec-21 Jun-22 Dec-22 Revenue A$ Mildura online 8 Confidential for discussion only. Not legally reviewed and numbers indicative only
Slide 10: Market opportunity is strong and growing
For personal use only Market opportunity is strong and growing Broad application across multiple indications Sales of legal medicinal cannabis in Australia set to grow from 1 million units Sleep disorder to an estimated 4-5 Million by 2025 Depression ASD (autism) 6000 PTSD 5000 4000 Anxiety Chronic
Slide 11: Lack of consistent quality and local supply is the opportunity
For personal use only Lack of consistent quality and local supply is the opportunity “I would prefer local product and producers like Cann because the product is fresh, lead times are shorter, the TGA rules are addressed and Only ~20% of sales it keeps jobs here . . . but there just isn’t the in Aus
Slide 12: Satipharm platform provides unique product development opportunities
Satipharm platform provides unique product development opportunities For personal use only S3/OTC (CBD) • Entering conversations with Haleon Doctor Prescribed (CBD &THC) • Registerable, differentiated & patent protected medicinal cannabis product • Microsphere formulation results in better stability
Slide 13: Priorities are clear, focus is strong
For personal use only Priorities are clear, focus is strong Significant scale-up of production at Mildura • Meet the needs of the rapidly growing market • Realise scale-based efficiencies including lower COGS and stronger margins • Be a stable, secure local supplier as TGA import regulations strengt
Slide 14: Moving to scaled production with a focus on quality, reliability and innovation
moving to scaled production with a focus on quality, reliability and innovation For personal use only • Mildura facility secures strong competitive advantage • Production is quickly moving to scale • Sales momentum is strong with positive outlook • Market opportunity is substantial and growing • Sat
Slide 15: Q&A
For personal use only Q&A
Slide 16: Contact
For personal use only Contact Peter Koetsier Chief Executive Officer peter.koetsier@canngrouplimited.com Deborah Ambrosini Chief Financial Officer deborah.ambrosini@canngrouplimited.com canngrouplimited.com | +61 3 9095 7188 15 Cann Group Limited Quality, Reliability, Innovation